HK2 and neoplasm: Additionally, 3-bromopyruvate (3-bp), another HK2 inhibitor, has been shown to reverse L-OHP resistance in CRC, and the combination of 3-bp and L-OHP effectively suppresses tumor progression compared to L-OHP treatment alone (Zhang et al. 2021).